ClinicalTrials.gg
RecruitingNCT06554301Updated Mar 19, 2026

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

A Phase 1 interventional study of empagliflozin in treatment pulmonary aerterial hypertension and placebo in treatment pulmonary aerterial hypertension in Pulmonary Arterial Hypertension, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by China National Center for Cardiovascular Diseases · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.

Planned enrollment
43rd of 56
72 · median 148
Started
2024
with 3 others
Phase 1
6 of 76
1 open now
Primary completion
2026-12
later than 8 of 23 live
Registered
63rd of 76
by date
Lead sponsor
3 of 76
China National Center for Cardiovascular Diseases

Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 43rd largest by planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 8 of the 23 other live ones, and was the 63rd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Pulmonary Arterial Hypertension with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are:

Based on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension.

Participants will:

Take empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old.
  2. Sign the form.
  3. Subjects who are willing and able to comply with the requirements of prescribed visits, treatment plans, laboratory examinations and other research procedures.
  4. PAH with symptoms was initially diagnosed and belonged to one of the following subgroups:

    A. Idiopathic pulmonary hypertension (IPAH); B. hereditary pulmonary hypertension (HPAH); C drug or toxin-induced PAH, based on previous exposure to drugs, chemicals or toxins, such as fenfluramine derivatives, other appetite suppressants, toxic rapeseed oil or L- tryptophan.

    D. PAH is accompanied by:

    A) connective tissue disease B) Congenital systemic-pulmonary shunt (surgical correction must be performed at least one year before screening, and there is no or no clinically insignificant systemic-pulmonary shunt [1.0≤ lung-systemic blood flow ratio (QP/QS)≤1.5]), according to the opinion of the researcher.

  5. Received right heart catheterization (RHC) at the time of screening or within 5 years before screening (if RHC is not performed, it will be performed during screening), which is consistent with the diagnosis of PAH and meets all the following criteria:

    A. mean pulmonary artery pressure (papm) > 20mmhg (at rest) B pulmonary arteriole wedge pressure (PAWP)≤15 mmHg (if reliable PAWP data cannot be obtained, left ventricular end diastolic pressure [LVEDP]≤15 mmHg).

    C pulmonary vascular resistance (PVR) > 2.00 wood units (> 160 dynes/sec/cm5).

  6. There are symptoms of WHO/ FC Grade II or III.
  7. Stable PAH targeted background oral therapy. Subjects received endothelin receptor antagonist (ERA) and/or phosphodiesterase inhibitor type 5 (PDE5-I) or soluble guanylate cyclase (sGC) agonist. Stability was defined as no change in dose or regimen within 30 days before baseline and during the duration of the study.
  8. 6-minute walking distance (6 MWD) ≥ 150m.
  9. If the subject is taking concomitant drugs that can affect PAH (for example, calcium channel blockers, digoxin or L- arginine supplements), the dose must be kept stable for at least 30 days before the baseline visit and throughout the study.
  10. If there is the possibility of pregnancy, both male and female subjects should agree to use a highly effective method during the whole study period (from informed consent to the end of follow-up).

Exclusion criteria

Exclusion Criteria:

  • 1) Subjects shall not have the following three or more risk factors for left ventricular dysfunction: (BMI)≥30 kg/m2 History of systemic hypertension

There is any of the following evidence to prove the history of major coronary artery disease:

A coronary angiographic evidence of a history of myocardial infarction or percutaneous coronary intervention or coronary artery disease (at least one coronary artery stenosis > 50%); B. Positive results of exercise provocation test and image evidence; C. previous coronary artery bypass surgery; D. stable angina pectoris; 2) Pulmonary function tests (PFTs) conducted within 180 days before or during the screening showed mild or above lung diseases. Subjects who meet any of the following criteria will be excluded: A. (FEV1)\<60% (expected value); or B total lung volume (TLC) \< 60% of the estimated value. 3) The evidence of thromboembolic disease is confirmed by lung ventilation/perfusion (V/Q) scanning or local standard diagnosis and treatment evaluation at the time of diagnosis or after diagnosis of PAH.

4) Severe chronic liver disease (i.e. grade C), portal hypertension, cirrhosis or complications of cirrhosis/portal hypertension (e.g., history of varicose bleeding, history of hepatic encephalopathy).

5) Confirm the active infection of virus (HBV) or virus (HCV).

6) Subjects whose (ALT) or aspartate aminotransferase (AST) level is more than or equal to 3 times the normal upper limit value () or whose total is more than or equal to 2 times ULN at the time of screening.

7) Chronic renal insufficiency at screening, which is defined as serum creatinine > 2.5 mg/dL or requiring dialysis support.

8) concentration \< 9 g/dL during screening. 9) diabetes. 10) cardiac function grade IV ( classification) 11) The subject has been treated with IV or SC prostacyclin pathway drugs (for example, epoprostol, triprostinil or iloprost) at any time before baseline (allowed to be used in pulmonary vasodilation test).

12) The subject has pulmonary vein occlusion disease. 13) Diagnosed and/or treated with malignant tumor within 5 years before screening, but excluding localized non- basal cell carcinoma or squamous cell carcinoma of the skin, or radical resection of cervical carcinoma in situ.

14) At the time of screening, there was a history of alcohol or drug abuse within 6 months.

15) Start the exercise-based cardiopulmonary rehabilitation program within 90 days of the screening period and/or during the study period.

16) Participated in other interventional clinical studies within 30 days before screening. It is allowed to participate in registered or observational studies at the same time, as long as the subjects meet all other selection criteria and comply with all research process requirements.

17) Any reason (for example, any past or intermittent diseases) that the respondent thinks may increase the risk of participating in the study or may affect the study analysis and damage the study participation or collaboration, so that the subject cannot participate in the study.

18) Those who are known to be allergic to Engelgin or any auxiliary materials. 19) According to the researcher\'s judgment, is less than 12 months.

20) Pregnant or lactating women.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Placebo comparator
    placebo in treatment pulmonary arterial hypertension

    Drug: placebo in treatment pulmonary aerterial hypertension

  • Experimental
    empagliflozin in treatment pulmonary arterial hypertension

    Drug: empagliflozin in treatment pulmonary aerterial hypertension

Interventions

  • Drugempagliflozin in treatment pulmonary aerterial hypertension

    On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.

  • Drugplacebo in treatment pulmonary aerterial hypertension

    On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. 6-minute walking distance

    6-minute walking distance

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Clinical deterioration event

    Clinical deterioration event

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Cardiac function index(NT-proBNP, WHO functional classification)

    Cardiac function index(NT-proBNP, WHO functional classification)

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Hemodynamic index

    Hemodynamic index

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Health-related quality of life (HRQoL) index

    Health-related quality of life (HRQoL) index

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Cardiac magnetic resonance (CMR)

    Cardiac magnetic resonance (CMR)

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 45 phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 15, 2024
StartActual
Oct 20, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554301
Collaborators
The Second Hospital of Shandong University, The First People's Hospital of Changzhou
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Oct 20, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Tingting Guo, M.D
Contact
18610094559@163.com
+86 18610094559

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion